Key facts
- It has raised $45.0M; the latest was Later Stage VC ($45.0M) in Sep 2025.
- Notable investors include Plug and Play Tech Center, Enterprise Ireland, European Union, Department of Enterprise, Trade and Employment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for OmniSpirant Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OmniSpirant Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OmniSpirant Therapeutics
Developer of regenerative gene therapies designed to treat respiratory disorders. The company offers therapies that use inhaled engineered stem cell exosomes that allow efficient intracellular delivery of therapeutic cargo, offering a way to correct deleterious mutations or reverse disease-causing states to deliver deoxyribonucleic acid to the airways and lungs, enabling patients to improve the delivery of therapeutic cargo into lung tissues.
- Sector
- Healthcare
- HQ
- Clonmel, Ireland
- Founded
- 2016
- Employees
- 8
- Website
- omnispirant.com/
- Ownership
- Privately Held (backing)
OmniSpirant Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OmniSpirant Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OmniSpirant Therapeutics in its N-PORT filings yet. We sweep new filings monthly.